CD7 and acute lymphoblastic leukemia: After allogeneic CAR-T cell therapies, patient 8 with KMT2D and HOX11L2 mutations had a CD7- relapse at month 3; patient 5 with T-ALL maintained MRD-negative remission for 9 months; patients 4 and 9 died during remission as previously described.